Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis
We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death. We followed 43 children with sickle cell disease from 2000 to 2009 after having a first clinical stroke, of whom 10 opted for HU therapy. HU use led to decreased stroke recurrence and death without significantly increasing the annual cost of care per patient (J$83,250 vs. J$76,901, Pâ=â0.491). The incremental cost effectiveness ratio (ICER) for prevention of stroke recurrence amounted to J$169,238 (US$1,900), while that for death prevention equalled J$635,843 (US$7,140). HU may be recommended when safe and affordable transfusion therapy is not feasible. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Colette CunninghamâMyrie, Abdullahi Abdulkadri, Andre Waugh, Susanna Bortolusso Ali, LesleyâGaye King, Jennifer KnightâMadden, Marvin Reid Tags: Brief Report Source Type: research
More News: Cancer | Cancer & Oncology | Children | Pediatrics | Sickle Cell Anemia | Stroke | Transfusion Therapy